Devices support Johnson & Johnson quarter 1 growth while observers mull acquisitions
This article was originally published in Clinica
Executive Summary
While Johnson & Johnson may have lost out to Boston in its bid to acquire Guidant, the diversified healthcare company could at least console itself with having gained $368m as compensation from Guidant for terminating their previous merger agreement. The one-off gain boosted J&J's first-quarter net earnings to $3.3bn - up 16.4% from the previous year - and more than offset $29m in acquisition charges incurred during that period.
You may also be interested in...
Pink Sheet Podcast: Leqembi Spending, Woodcock’s Next Act, Pneumococcal Vaccine Development
Pink Sheet editors discuss Medicare spending projections for the Alzheimer’s treatment Leqembi, Janet Woodcock’s new post-FDA role, and ongoing preparations for new pneumococcal vaccines that will reach the market soon.
Investors Go Berserk For Viking, Putting It Top Of Q1 Winners
The top 10 biggest share price winners and losers in Q1 from Evaluate show the investor frenzy for obesity drugs continues, while companies with governance doubts see shareholders retreat.
EU Consults On What Constitutes Personal & Commercially Confidential Data In Marketing Applications
Based on their experience with dealing with requests for access to documents over the past 12 years, EU regulators have proposed updating their guideline that provides for a harmonized approach to protecting personal data and business secrets in marketing authorization applications.